3 Issued U.S. Patents · Active Through 2037

A Patented Platform for
Biology-Driven
Transdermal Formulations

Our issued U.S. patent estate protects a family of differentiated transdermal glutathione formulations. Each begins with a defined biological objective, with complementary bioactive compounds selected for that purpose — creating a platform that expands across cosmeceutical, nutraceutical, pharmaceutical and clinical markets.

Cosmeceutical Nutraceutical Pharmaceutical Sports & Longevity Clinical & Oncology
Download Executive Overview ↓ Explore the Platform
3
Issued U.S. Patents
2037
Patent Expiration
19+
Years Clinical Experience
Franz Cell
Independent Permeation Study
Day 14
Visible Improvement in Pilot
5
Recited Claim Outcomes

As Seen In

VOGUE
ELLE
SHAPE
HOUSE & GARDEN
DAILY VANITY
WOMEN OF INSPIRATION
Platform Design Philosophy

Every Formulation Begins
With a Biological Objective.

Complementary bioactive compounds are selected for their mechanistic rationale, then formulated within GlutaTherapy’s transdermal platform where skin delivery offers a meaningful therapeutic or commercial advantage over oral or injected routes.

01

Define the biological objective

Scar remodeling, inflammatory regulation, tissue repair, pigment correction — the outcome is specified before any ingredient is chosen.

02

Select for mechanistic fit

Glutathione is paired with complementary bioactive compounds chosen for their rationale against that specific objective — not for marketing appeal.

03

Formulate transdermally where it wins

Skin delivery is applied where it offers a real advantage over oral bioavailability or clinical injection — then protected.

Rather than developing isolated products, GlutaTherapy has built a repeatable framework for designing indication-specific formulations. The issued patents protect the compositions this framework has produced; the framework itself is what continues to produce them.

The Platform

One Protected Base.
Unlimited Commercial Reach.

GlutaTherapy holds an issued U.S. patent estate covering delivery of glutathione in both topical cream and adhesive patch form — protected through 2037.

While most glutathione products rely on oral supplementation (poor bioavailability) or IV injection (requiring clinical administration), GlutaTherapy's platform enables localized, targeted transdermal delivery — absorbed directly through the skin without injection or oral supplementation.

Three patents build layered coverage across formulation, delivery format and liposomal encapsulation — closing the most common design-around pathways. The estate is structured to be acquired as one position.

The patent claims recite five therapeutic outcomes achieved without injection or oral supplementation. Beyond these, the specification discloses more than thirty worked formulations spanning scar repair, hyperpigmentation, eczema, and acne — creating commercial applications across multiple markets from a single protected technology base.

US 10,314,779 B2 · Granted June 2019
Transdermal Glutathione Delivery — Foundation Patent
Core formulation claim covering cream and patch delivery using glutathione with penetration-enhancing co-formulants. Establishes the foundational IP position.
Active · Expires 2037
US 10,548,830 B2 · Granted February 2020
Transdermal Patch — Waterproof Adhesive Format
Claims cover the latex-free hypoallergenic adhesive patch and its waterproof form — sustained delivery over an extended wear period. Directly relevant to the advanced wound care dressing design space, and closes competitor design-around pathways on delivery format.
Active · Expires 2037
US 12,048,729 B2 · Granted July 2024
Advanced Liposomal Delivery Technology
Most recent and most advanced patent. Extends the platform into liposomal encapsulation — the cutting edge of transdermal bioavailability — further protecting the platform against next-generation competitors.
Active · Expires 2037
Delivery Format

Cream or Patch — Both Protected

Format 1

Transdermal Cream

Latex-free, hypoallergenic topical formulation applied directly to skin. Suitable for cosmeceutical retail, clinical, and aesthetic medicine channels. Broad consumer and professional market applicability.

Format 2

Adhesive Patch

Controlled, sustained transdermal delivery via hypoallergenic adhesive patch. Opens pharmaceutical, nutraceutical, clinical, and institutional channels. Enables precise dosing and extended release profiles.

Therapeutic Applications

One Formulation Platform.
Six Commercial Markets.

Five therapeutic outcomes are recited in the patent claims. The specification discloses over thirty formulations extending into scar repair, hyperpigmentation, eczema, and acne — each opening distinct commercial channels with their own buyer ecosystems.

🔬

Dermatologic & Aesthetic

Reduction of facial wrinkles, skin brightening, hyperpigmentation correction, and barrier repair. Minimum 10% increase in skin moisture retention documented in patent claims.

CosmeceuticalMed SpaAesthetics
🩹

Wound Care & Scar Repair

Keloid reduction, surgical scar remodeling, burn scar treatment, trauma scarring, and advanced tissue repair. Visible improvement documented at Day 14 in a preliminary investigator pilot (uncontrolled, unblinded).

ClinicalSurgicalWound Care
😴

Sleep Regulation

Recited claim for regulation of sleep. Opens the sleep supplement and wellness market — one of the fastest-growing nutraceutical categories globally.

NutraceuticalWellnessConsumer
⚡

Energy & Cognitive Performance

Patented claims for increased energy during awake periods and improved concentration. Directly applicable to sports nutrition, biohacking, and functional wellness markets.

Sports NutritionLongevityBiohacking
💊

Joint & Muscular Pain Relief

Patented reduction of joint and muscular pain without injection or oral supplementation. Applicable to sports recovery, pain management, and pharmaceutical channels.

PharmaceuticalSportsRecovery
🏥

Clinical & Oncology Support

Glutathione depletion is well-documented in oncology patients. Transdermal delivery without injection opens institutional clinical channels including radiation recovery and oncology-supportive care.

PharmaceuticalOncologyInstitutional
Patented Outcomes

What The Patents Protect

Five therapeutic outcomes are explicitly recited across the patent family. A sixth application area — tissue and wound repair — is supported by formulations disclosed in the specification.

😴

Sleep Regulation

Recited claim — regulation of sleep

⚡

Increased Energy

Recited claim — increased energy during awake periods

🧠

Improved Concentration

Recited claim — improved concentration during awake periods

✨

Facial Wrinkle Reduction

Recited claim — with ≥10% increase in skin moisture retention

🦴

Joint & Muscular Pain

Recited claim — without injection or oral supplementation

🩹

Scar & Tissue Repair

Specification-disclosed — worked formulations for post-surgical scarring, hyperpigmentation, eczema & acne

Pilot Evidence

Documented. Photographed. Disclosed.

Day 1 - Keloid Scar Day 1
Day 14 - Keloid Scar Day 14

Keloid scar · Post-melanoma excision · Clinical photography available under NDA

Investigator Pilot · 4-Week

Visible Results.
Measurable Outcomes.

  • ✓
    Reduced inflammation
  • ✓
    Decreased redness
  • ✓
    Flatter scar profile
  • ✓
    Reduced itching and pain (patient-reported)
  • ✓
    Improved tissue texture

Full clinical photography and evaluation documentation available to qualified buyers under NDA.

Franz Cell Testing

Independent permeation study on intact human cadaver skin — confirms glutathione crosses the skin barrier

Stability Testing

Formulation stability confirmed — commercially ready for scale

Manufacturing Ready

Manufacturing pathways established and validated

Why This Platform Is Different

Solving Glutathione's
Biggest Problem

The Problem: Glutathione Bioavailability
Oral and IV delivery are limited, invasive, or impractical at scale
Oral Supplementation
Poor bioavailability — destroyed by digestive enzymes before absorption
IV / Injection
Requires clinical setting — not scalable for consumer or nutraceutical markets
GlutaTherapy Transdermal Platform
Direct skin absorption — no injection, no degradation, targeted delivery. Protected through 2037.
Liposomal Enhancement (Patent 3)
Most advanced formulation — liposomal encapsulation for maximum cellular uptake

A Platform, Not A Product

Most IP acquisitions involve a single product with a single application. GlutaTherapy is fundamentally different — it is a formulation platform — one protected delivery architecture applied across six distinct commercial markets.

A strategic acquirer doesn't inherit one revenue stream. They inherit the ability to launch into cosmeceutical, nutraceutical, pharmaceutical, sports nutrition, longevity, and clinical markets — all from a single IP transaction.

The Liposomal Advantage

Patent 3 (granted 2024) introduces liposomal encapsulation — the most advanced transdermal delivery technology currently available. Liposomal delivery dramatically improves cellular uptake and is the subject of significant R&D investment industry-wide.

GlutaTherapy already has this protected. Competitors building toward liposomal glutathione delivery must navigate an issued patent estate that extends through 2037.

Continuation Patent Strategy

The three patents are not separate inventions — they are a layered estate built from a single 2017 priority filing. Each continuation extends coverage into an adjacent pathway — formulation, then delivery format, then liposomal encapsulation.

The estate is offered as a single position — creating a clean, single-transaction opportunity for a strategic buyer.

Target Markets

Strategic Buyer Categories

The platform's multi-outcome patent claims create four distinct buyer ecosystems — each with independent budget, distribution infrastructure, and strategic rationale for acquisition.

Market 1

Cosmeceutical & Aesthetic

Anti-aging, skin brightening, hyperpigmentation, scar aesthetics, and post-procedure recovery. Topical cream format ideal for retail, professional, and med spa channels. Glutathione is one of the most searched aesthetic ingredients globally.

Channel fit: retail, professional and med spa cosmeceutical brands
Market 2

Nutraceutical & Longevity

Sleep regulation, energy and cognitive performance — all recited claim outcomes — via patch format. The longevity and biohacking sector is actively acquiring proprietary delivery IP. Transdermal patch delivery is a premium differentiation signal in this market.

Channel fit: nutraceutical, longevity and functional wellness brands
Market 3

Pharmaceutical & Clinical

Non-injection glutathione delivery for clinical settings — oncology support, wound management, radiation recovery, and institutional channels. The pharmaceutical channel represents the highest-value licensing opportunity given therapeutic claim breadth.

Channel fit: pharmaceutical companies with transdermal pipelines, wound care specialists, oncology-adjacent companies
Market 4

Sports Nutrition & Recovery

Joint and muscular pain relief, energy, and recovery — all patented claims with direct sports nutrition applicability. Transdermal delivery is a premium format in this market, commanding higher price points and strong brand differentiation.

Channel fit: sports nutrition brands, recovery technology companies, professional sports partnerships
Strategic Rationale

Why Strategic Buyers Engage Now

Category exclusivity through 2037 across six high-growth markets — available as a single IP transaction. The question is not whether transdermal glutathione delivery becomes mainstream. It is who owns the IP when it does.

Breadth of Granted Claim Scope

Granted claims span composition, delivery format and five recited therapeutic outcomes — in both cream and adhesive patch form. Few transdermal glutathione estates combine formulation and format coverage this way, and that breadth is what makes a single transaction sufficient.

2037 Protection — First Mover Window Is Now

Patent protection runs through 2037. A buyer who acts now secures 11+ years of exclusivity. A buyer who waits watches a competitor acquire the same window first.

One Acquisition, Multiple Markets

A single transaction unlocks commercial pathways across medical aesthetics, wound care, anti-aging, nutraceuticals, and longevity — each independently addressable without additional IP.

Manufacturing Pathway Established

Formulation is commercially proven and stability-tested. A buyer is acquiring a deployment-ready asset, not a development project.

Independent Testing Completed

Franz cell permeation confirmed independently on intact human cadaver skin. A preliminary investigator pilot — uncontrolled and unblinded — documented visible improvement at Day 14. Clinical photography available under NDA.

Secure Category Leadership

Glutathione is already a $2B+ IV market in Asia. Transdermal delivery solves the bioavailability problem oral and IV routes cannot. The buyer who owns this IP defines the category.

Market Opportunity
Market 2026 Size Growth (CAGR)
Medical Aesthetics $32B 13.7% annually
Wound Care & Scar $26B 4.3% annually
Anti-Aging & Longevity Skincare $60B+ 8.5% annually
Nutraceuticals & Wellness $550B+ 10.6% annually

Sources: Fortune Business Insights, Grand View Research, Precedence Research (2026)

Partnership Structures

How We Work Together

GlutaTherapy is open to multiple engagement structures depending on the strategic fit and commercial goals of the partner.

Option 01

Full IP Acquisition

Complete purchase of all three patents and Glutatherapy™ trademark. Clean transaction, full ownership transfer.

Option 02

Exclusive License

Exclusive licensing rights by market category, geography, or application — with retained patent ownership.

Option 03

Strategic Co-Development

Joint development partnership to expand the platform into new therapeutic areas or delivery formats.

Option 04

Distribution & Joint Venture

Commercial distribution agreements or joint venture structures for specific markets or territories.

The Inventor

Built From Clinical Practice

GlutaTherapy was founded by Rachel Sarah Levine, MSc, DSHOMED — a clinician with 19 years of experience treating complex chronic conditions using integrative and naturopathic medicine.

The platform was developed from firsthand clinical frustration with existing glutathione delivery methods — and built to solve a real, documented problem in both clinical and consumer health contexts.

The result is a patent estate grounded in clinical reality, validated independently, and commercially ready.

MSc, DSHOMED — Advanced clinical credentials
19+ years clinical experience in chronic disease
Sole inventor — all three U.S. patents
Independent Franz Cell permeation validation
Stability testing completed — commercially ready
Manufacturing pathways established
Glutatherapy™ trademark
Commercial Validation

The Platform Has Been
Tested in Market.

The technology was commercialized under the Susona brand to validate formulation, manufacturing, and consumer acceptance in both cream and patch format. An acquirer is not underwriting an untested formulation — the product has shipped, and the market responded.

"I have tried almost all of the Glutathione Face Cream online. This is the best and the most effective in the market. You can see the difference immediately."

KK
Kamyar Katiraie
Verified purchaser · Cream format

"I love the convenience of Susona's Glutathione patches. Peel and get a dose of glutathione all day long! I immediately feel the difference with a boost of energy!"

S
Silvina
Verified purchaser · Patch format

"The scent makes you stop, breathe and feel the goodness. I have tried just about every good cream sold at Wholefoods and many of the best creams out there and this is the one. My skin feels younger softer and yes I am more at peace with each pump."

DM
Donna Morton
Verified purchaser · Cream format
Get In Touch

Ready to Explore a Partnership?

GlutaTherapy is actively engaging qualified strategic partners across all market categories. Initial conversations are confidential and conducted under mutual NDA.

rachel@glutatherapy.com →
Direct · Confidential · Responded within 48 hours
Download Executive Overview

All inquiries are confidential. NDA available upon request.

Thank You

Your inquiry has been received. We'll be in touch within 48 hours to discuss next steps.